View all trials
Are you a member? Sign in above to view additional information
  • Study title
    A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed, Refractory or Progressive Neuroblastoma
  • Protocol ID
    ANBL1821
  • Disease
    Disease Type Disease Subtype
    Solid tumours
    Neuroblastoma
  • Eligibility criteria
  • Study Status
    Open
  • Location(s)
    Queensland Children's Hospital
    • Centre Study Status:
      Open
    • Notes:
  • Phase
    Phase 2
  • Study type
    Treatment
  • Diagnosis stage
    Relapse/refractory
  • Study open date
    N/A
  • Study close date
    N/A
  • Study chair
  • Sponsor
    Children's Oncology Group
Back to search results